로딩 중…
지수 로딩 중…
LabGenomics Co., Ltd.
084650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩878-4.77%
2026-06-19
Price Chart
LabGenomics Co., Ltd.-67.72%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 65.18B KRW |
| Revenue | 84.19B KRW |
| Net Income | -63.71B KRW |
| Total Assets | 234.96B KRW |
| Net Assets | 149.16B KRW |
| Employees | 186 |
| Value | |
| P/B | 0.44x |
| P/S | 0.77x |
| FCF Yield | -46.85% |
| Profitability | |
| ROE | -42.71% |
| ROA | -27.11% |
| Op. Margin | -61.74% |
| Revenue Growth | -18.13% |
| Financial Health | |
| Debt Ratio | 157.52% |
| FCF | -30.54B KRW |
| Cash | 3.86B KRW |
| Current Ratio | 1.17x |
| Performance | |
| 1Y Return | -67.72% |
| 1M Return | -35.91% |
| From 52W High | -70.39% |
| 1Y MDD | -71.60% |
| Trading | |
| Volume | 647,388 shares |
| Foreign Own. | 3.32% |
| Per Share | |
| EPS | -858 KRW |
| BPS | 2,009 KRW |
Company Info
Labgenomics, established in 2002 as a specialized genomics molecular diagnostics company and headquartered in Seongnam-si, Gyeonggi-do, was listed on KOSDAQ in 2014. In 2024, the company officially entered the American diagnostic market by acquiring U.S. CLIA labs QDx Pathology Services and IMD, securing a diagnostic service network across the United States. It operates various genomics molecular diagnostics businesses, having commercialized Korea's first Next-Generation Sequencing (NGS)-based non-invasive prenatal testing for fetal abnormalities and established a network of over 3,000 hospitals nationwide.